Dean Harvey Comments on Valeant-Kadmon Pharma Antitrust Challenges

Dean Harvey Comments on Valeant-Kadmon Pharma Antitrust Challenges

Reuters has published a compelling analysis of ongoing challenges facing pharmaceutical “rogue” Valeant with a focus on its price-inflated drug Syprine and its relationship with also-beleagured pharma company Kadmon. Among other issues, Valeant has been singled out as a prime offender in the realm of hyper-inflated pharmaceutical drugs, with, Syprine, its life-saving Wilson’s disease liver ailment treatment costing some patients nearly $300,000 for a year’s use (in 2011, Valeant priced the drug at less than $1,000 for 100 capsules, a rate that rose by 2015 to over $21,000 for the same dose). [Read more…]